Valeant Pharma (VRX) Reports Q3 EPS of $3.69, Beating Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. XYZ
8. CVS
9. SPY
10. SWKS

Go back to Valeant Pharma (VRX) Reports Q3 EPS of $3.69, Beating Views

Valeant Announces Third-Quarter 2017 Results

November 7, 2017 7:01 AM EST

LAVAL, Quebec, Nov. 7, 2017 /PRNewswire/ --

Strong Third-Quarter 2017 Financial Results Revenues of $2,219 million GAAP Net Income of $1,301 million Adjusted Net Income (non-GAAP) of $367 million GAAP Cash Flow From Operations of $490 million; Year-to-Date of $1,712 million Adjusted EBITDA (non-GAAP) of $951 million Delivered Strong Organic Growth1 (non-GAAP) in Bausch + Lomb/International Segment and Salix Business Exceeds $5 Billion Debt Reduction Commitment Early Updates 2017 Full-Year Revenue and Maintains Adjusted EBITDA (non-GAAP) Guidance Range Despite Asset Divestitures

Valeant... More